TEVIMBRA
GrowthmAbBLASOLUTIONINJECTION
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEVIMBRA is pd-1 ligands pd-l1 and pd-l2, to the pd-1 receptor found on t cells, inhibits t-cell proliferation and cytokine production. Approved for metastatic esophageal squamous cell carcinoma (escc) after prior systemic chemotherapy. First approved in 2024.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVIMBRA is a monoclonal antibody (mAb) therapeutic approved as a biologic license application (BLA) in March 2024, delivered as an injectable solution. The specific indication and mechanism of action are not publicly disclosed in available data. The drug targets patients requiring parenteral monoclonal antibody therapy.
Growth
Early-stage growth phase with moderate competitive pressure (30/100) suggests expanding commercial team and increasing investment in market penetration and field infrastructure.
Mechanism of Action
PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.